LIVAZO Trademark

Trademark Overview

On Tuesday, March 3, 2020, a trademark application was filed for LIVAZO with the United States Patent and Trademark Office. The USPTO has given the LIVAZO trademark a serial number of 79283662. The federal status of this trademark filing is ABANDONED - AFTER EX PARTE APPEAL as of Monday, November 15, 2021. This trademark is owned by KOWA COMPANY, LTD. The LIVAZO trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of conditions and diseases of the circulatory system
livazo

General Information

Serial Number79283662
Word MarkLIVAZO
Filing DateTuesday, March 3, 2020
Status603 - ABANDONED - AFTER EX PARTE APPEAL
Status DateMonday, November 15, 2021
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of conditions and diseases of the circulatory system

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, April 23, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameKOWA COMPANY, LTD
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressJP

Trademark Events

Event DateEvent Description
Monday, April 10, 2023NEW REPRESENTATIVE AT IB RECEIVED
Tuesday, December 20, 2022FINAL DECISION TRANSACTION PROCESSED BY IB
Wednesday, November 30, 2022FINAL DISPOSITION NOTICE SENT TO IB
Wednesday, November 30, 2022FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Monday, August 8, 2022REFUSAL PROCESSED BY IB
Tuesday, November 30, 2021ABANDONMENT NOTICE MAILED - AFTER EX PARTE APPEAL
Monday, November 15, 2021ABANDONMENT - AFTER EX PARTE APPEAL
Monday, November 15, 2021EXPARTE APPEAL TERMINATED
Sunday, October 10, 2021NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Monday, October 4, 2021EXPARTE APPEAL DISMISSED - FAILURE TO FILE BRIEF
Wednesday, September 22, 2021NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, September 22, 2021NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Tuesday, July 20, 2021NOTIFICATION OF ACTION DENYING REQ FOR RECON E-MAILED
Tuesday, July 20, 2021ACTION DENYING REQ FOR RECON E-MAILED
Tuesday, July 20, 2021ACTION CONTINUING FINAL - COMPLETED
Wednesday, June 30, 2021TEAS REQUEST FOR RECONSIDERATION RECEIVED
Wednesday, June 30, 2021EX PARTE APPEAL-INSTITUTED
Wednesday, June 30, 2021JURISDICTION RESTORED TO EXAMINING ATTORNEY
Wednesday, June 30, 2021EXPARTE APPEAL RECEIVED AT TTAB
Monday, January 11, 2021NOTIFICATION OF FINAL REFUSAL EMAILED
Monday, January 11, 2021FINAL REFUSAL E-MAILED
Monday, January 11, 2021FINAL REFUSAL WRITTEN
Saturday, December 19, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, December 18, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, December 18, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, July 17, 2020REFUSAL PROCESSED BY IB
Friday, June 26, 2020NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Friday, June 26, 2020REFUSAL PROCESSED BY MPU
Wednesday, May 27, 2020NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Tuesday, May 26, 2020NON-FINAL ACTION WRITTEN
Wednesday, May 20, 2020ASSIGNED TO EXAMINER
Tuesday, April 28, 2020APPLICATION FILING RECEIPT MAILED
Thursday, April 23, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, April 21, 2020LIMITATION FROM ORIGINAL APPLICATION ENTERED
Thursday, April 16, 2020SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB

Related Keywords

livazo circulatory system diseases conditions preparations treatment pharmaceutical